Alembic Pharma Peer Comparison
NSE: APLLTD | BSE: 533573
₹1,044.35
As on 18-Nov-2026IST
Market cap
₹20,512 Cr
Revenue (TTM)
₹8,477 Cr
P/E Ratio
24.3
P/B Ratio
3.5
Div. Yield
1.1 %
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
20,512 | 32,712 | 32,943 | 31,813 | 27,509 |
Revenue (₹ Cr) |
8,477 | 1,593 | 3,751 | 9,779 | 2,100 |
Net Profit (₹ Cr) |
841.46 | 438.64 | 405.00 | -270.51 | 324.79 |
Net Margin (%) |
9.84 | 27.16 | 10.48 | -2.71 | 15.36 |
RoE (%) |
15.85 | 25.02 | 7.91 | -2.55 | 24.02 |
Price to Earnings |
24.31 | 74.49 | 80.35 | -- | 84.69 |
Price-To-Book |
3.45 | 17.61 | 6.39 | 3.91 | 19.42 |
Income Statement (₹ Cr)
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
8,477.28 | 1,592.52 | 3,751.00 | 9,778.62 | 2,100.17 |
|
Total Income
|
8,548.32 | 1,615.23 | 3,863.00 | 9,993.26 | 2,114.53 |
|
Total Expenditure
|
7,060.73 | 969.32 | 2,984.00 | 8,578.44 | 1,600.14 |
|
EBITDA
|
1,416.55 | 623.20 | 767.00 | 1,200.18 | 500.03 |
|
Depreciation
|
367.22 | 41.96 | 228.00 | 887.82 | 57.00 |
|
EBIT
|
1,049.33 | 581.24 | 539.00 | 312.36 | 443.03 |
|
Interest
|
111.74 | 4.21 | 218.00 | 347.94 | 40.83 |
|
Other Income
|
71.04 | 22.71 | 112.00 | 214.64 | 14.37 |
|
Exceptional Items
|
-66.99 | 0.00 | 12.00 | -216.88 | 0.00 |
|
Profit before Tax
|
941.64 | 599.74 | 445.00 | -37.82 | 416.57 |
|
Provision for Tax
|
100.18 | 161.10 | 40.00 | 232.69 | 91.78 |
|
Profit after Tax
|
841.46 | 438.64 | 405.00 | -270.51 | 324.79 |
Liabilities (₹ Cr)
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,944.47 | 1,857.45 | 5,158.00 | 8,142.24 | 1,416.33 |
|
Minority Interest
|
4.16 | 0.51 | 5.00 | 0.55 | 0.05 |
|
Non-Current Liabilities
|
495.52 | 47.15 | 1,617.00 | 5,213.99 | 376.76 |
|
Current Liabilities
|
3,098.56 | 253.37 | 1,785.00 | 5,158.51 | 952.98 |
|
Total Liabilities
|
8,855.62 | 1,983.96 | 8,578.00 | 17,723.32 | 2,326.71 |
Assets (₹ Cr)
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
4,249.47 | 1,132.12 | 5,527.00 | 10,687.30 | 798.30 |
|
Current Assets
|
5,222.63 | 1,012.00 | 2,764.00 | 7,253.65 | 1,747.21 |
|
Total Assets
|
8,855.62 | 1,983.96 | 8,578.00 | 17,723.32 | 2,326.71 |
|
Total Debt*
|
1,360.85 | 26.49 | 2,125.00 | 5,495.48 | 259.37 |
|
Net Current Assets
|
2,124.07 | 758.64 | 979.00 | 2,095.14 | 794.23 |
|
Contingent Liabilities
|
160.39 | 17.25 | 768.26 | 95.72 | 19.09 |
Cashflow (₹ Cr)
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
782.73 | 292.17 | 390.00 | 1,652.60 | 205.05 |
|
Cash Flow from Investing Activities
|
-506.06 | -265.94 | -241.00 | -826.03 | -409.72 |
|
Cash from Financing Activities
|
-163.78 | 4.10 | -54.00 | -38.98 | 283.07 |
|
Net Cash Inflow / Outflow
|
112.89 | 30.33 | 95.00 | 787.59 | 78.39 |
Ratios
Profitability Ratios
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.74 | 32.42 | 6.79 | 1.24 | 29.22 |
|
ROE (%)
|
15.85 | 25.02 | 7.91 | -2.55 | 24.02 |
|
ROA (%)
|
9.39 | 22.40 | 4.65 | -1.56 | 14.30 |
|
EBIT Margin (%)
|
12.38 | 36.50 | 14.37 | 3.19 | 21.09 |
|
Net Margin (%)
|
9.84 | 27.16 | 10.48 | -2.71 | 15.36 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
19.68 | 45.18 | 25.70 | 9.43 | 46.25 |
|
EBIT Growth (%)
|
24.88 | 115.51 | 139.56 | -3.72 | 60.95 |
|
Net Profit Growth (%)
|
33.35 | 95.80 | 894.12 | -199.34 | 89.41 |
|
EPS Growth (%)
|
45.18 | 63.29 | 599.72 | -410.28 | 76.32 |
|
Book Value Growth (%)
|
9.32 | 26.03 | 13.47 | 0.33 | 144.31 |
Valuation Ratios
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.27 | 74.49 | 82.45 | -152.98 | 84.52 |
|
Price / Book Value
|
3.45 | 17.61 | 6.39 | 3.91 | 19.42 |
|
Dividend Yield (%)
|
1.15 | 0.06 | 0.00 | 0.00 | 0.09 |
|
EV/EBITDA
|
15.30 | 52.17 | 44.86 | 29.96 | 54.84 |
|
Market Cap (₹ Cr)
|
13,008.55 | 20,944.75 | 19,071.62 | 18,108.89 | 12,753.19 |
Solvency Ratios
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.02 | 0.02 | 0.28 | 0.55 | 0.13 |
|
Short term debt to equity ratio
|
0.21 | 0.00 | 0.09 | 0.09 | 0.05 |
|
Current Ratio
|
1.69 | 3.99 | 1.55 | 1.41 | 1.83 |
|
Quick Ratio
|
0.83 | 2.89 | 1.00 | 0.77 | 1.00 |
|
Interest Coverage
|
9.43 | 143.52 | 3.04 | 0.89 | 11.20 |
Operating Efficiency Ratios
| Alembic Pharma | Acutaas Chemicals | Wockhardt | Piramal Pharma | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.37 | 22.50 | 16.85 | 23.05 | 27.51 |
|
Asset Turnover
|
0.95 | 0.81 | 0.43 | 0.56 | 0.92 |
|
Receivable days
|
36.70 | 88.98 | 58.75 | 78.20 | 40.13 |
|
Inventory Days
|
61.45 | 56.04 | 75.82 | 93.30 | 60.29 |
|
Payable days
|
157.72 | 99.95 | 186.21 | 226.14 | 232.47 |
|
Cash Conversion Cycle
|
-59.57 | 45.07 | -51.64 | -54.64 | -132.04 |